Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Revolution Medicines ( (RVMD) ) just unveiled an announcement.
On September 10, 2025, Revolution Medicines reported updates from its Phase 1 studies on daraxonrasib, a RAS(ON) multi-selective inhibitor, for treating metastatic RAS-mutant pancreatic ductal adenocarcinoma (PDAC). The studies showed promising safety, tolerability, and efficacy data in both second-line and first-line settings, with notable objective response rates and disease control rates. These findings support further development and a planned Phase 3 trial, potentially enhancing the company’s position in the oncology market.
The most recent analyst rating on (RVMD) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Revolution Medicines stock, see the RVMD Stock Forecast page.
Spark’s Take on RVMD Stock
According to Spark, TipRanks’ AI Analyst, RVMD is a Neutral.
Revolution Medicines has a moderate overall score primarily due to financial challenges such as declining revenues and persistent net losses, common in biotech firms. The technical analysis indicates a bearish trend, and the valuation remains unattractive with a negative P/E ratio. However, the positive strides in the RAS(ON) inhibitor pipeline and strong liquidity position partially offset these challenges, as highlighted in the recent earnings call.
To see Spark’s full report on RVMD stock, click here.
More about Revolution Medicines
Revolution Medicines, Inc. operates in the biopharmaceutical industry, focusing on developing targeted therapies for RAS-mutant cancers. The company is advancing its RAS(ON) inhibitor, daraxonrasib, as a treatment for pancreatic ductal adenocarcinoma (PDAC), aiming to address unmet medical needs in oncology.
Average Trading Volume: 2,269,638
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.68B
See more insights into RVMD stock on TipRanks’ Stock Analysis page.